FDA Issues Warning Letter to Amphastar Subsidiary IMS
55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Amphastar Pharmaceuticals ( (AMPH) ) just unveiled an update.
On July 2, 2026, Amphastar’s subsidiary International Medication Systems received a warning letter from the FDA following a December 2025 inspection of its South El Monte, California drug manufacturing facility. The letter cites violations of current Good Manufacturing Practice regulations related to investigation procedures, environmental monitoring, material handling, and manufacturing equipment.
The FDA did not order IMS to stop or restrict product distribution from the plant or mandate further recalls, allowing continued manufacturing while IMS implements its remediation plan. IMS has begun corrective actions since the inspection and is preparing a risk assessment and remediation plan, while Amphastar evaluates potential impacts on its operations amid uncertainty over FDA’s satisfaction with the response and the possibility of further regulatory or legal action.
The most recent analyst rating on (AMPH) stock is a Sell
with a $20.00 price target.
To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock,
see the AMPH Stock Forecast page.
Spark’s Take on AMPH Stock
According to Spark, TipRanks’ AI Analyst, AMPH is a Neutral.
The score reflects solid fundamentals (profitability, strong cash flow, and currently low leverage) and a supportive earnings multiple, offset by weak technicals (price below key moving averages with negative MACD and sub-50 RSI) and a mixed earnings update where margins and EPS fell sharply due to pricing/340B and product headwinds despite portfolio growth initiatives and buybacks.
To see Spark’s full report on AMPH stock,
click here.
More about Amphastar Pharmaceuticals
Amphastar Pharmaceuticals operates in the pharmaceutical industry through subsidiaries such as International Medication Systems, Limited, which manufactures finished drug products at facilities including its South El Monte, California plant. The company focuses on producing and supplying medications that must comply with U.S. Food and Drug Administration requirements for current Good Manufacturing Practice standards.
Average Trading Volume: 619,249
Technical Sentiment Signal: Sell
Current Market Cap: $864.7M
See more insights into AMPH stock on TipRanks’ Stock Analysis page.
